Anti-Human TAP2 (Clone CPTC-TAP2-1) – Purified No Carrier Protein

TAP2 synthetic peptide EAVGGLQTVR

This recombinant monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Liquid

Recombinant antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

EB0141A-2G9-H3/K2 activity is directed against human TAP2 peptide sequence EAVGGLQTVR.

CPTC-TAP2-1

MHC class I molecules bind peptides generated by the degradation of cytosolic proteins, and then display those peptides on the cell surface¹. Generally, these peptides are derived from normal metabolism, but they can also be derived from foreign proteins during viral infection or allotransplantation. When peptides are recognized as foreign, cytotoxic T lymphocytes specific to the MHC class I-peptide complex kill the presenting cell.

TAP2 is a member of the MDR/TAP subfamily of ABC transporters involved in antigen presentation². TAP2, when complexed with TAP1, acts as a peptide transporter that ferries short peptides from the cytoplasm across the endoplasmic reticulum (ER) membrane³. The antigenic peptides are then complexed with class I MHC molecules and presented on the cell surface to receptors on CD8+ cytotoxic T lymphocytes². This recognition process maintains host immunity against viruses and tumors. Additionally, the TAP complex with tapasin aids in the assembly of class I MHC molecules in the ER. TAP2 is an integral membrane protein that consists of an N- terminal membrane spanning domain and a C-terminal cytosolic ABC ATPase. Dysregulation of TAP2 is associated with ankylosing spondylitis, insulin-dependent diabetes mellitus, and celiac disease³.

EB0141A-2G9-H3/K2 was generated for use in immuno-MRM assays in rabbit using a synthetic peptide derived from human TAP2, EAVGGLQTVR⁴. EB0141A-2G9-H3/K2 does not detect TAP2 by immunohistochemistry, reverse phase protein array, or Western blot⁵.

TAP2 is present in the endoplasmic reticulum.

TAP1, TAPBP, classical and nonclassical MHCI molecules, Epstein-Barr virus BLNF2a, herpes simplex virus US12/ICP47, adenovirus E3-19K glycoprotein

1 Yoshida R. Adv Immunol. 124:207-247. 2014.
2 Bouvier M. Mol Immunol. 39(12):697-706. 2003.
3 https://www.ncbi.nlm.nih.gov/gene/6891.
4 Whiteaker JR, Lundeen RA, Zhao L, et al. Front Immunol. 12:765898. 2021.
5 https://antibodies.cancer.gov/detail/CPTC-TAP2-1#CPTC-TAP2-1